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A B S T R A C T
The new severe acute respiratory syndrome- coronavirus 2 is reported to affect the nervous system. Among the
reports of the various neurological manifestations, there are a few documented specific processes to explain the
neurological signs. We report a para-infectious encephalitis patient with clinical, laboratory, and imaging
findings during evolution and convalescence phase of coronavirus infection. This comprehensive overview can
illuminate the natural history of similar cases. As the two previously reported cases of encephalitis associated
with this virus were not widely discussed regarding the treatment, we share our successful approach and add
some recommendations about this new and scarce entity.
1. Introduction
As the new emerging coronavirus, severe acute respiratory syn-
drome- coronavirus 2 (SARS- CoV 2), spreads all over the world, new
features of this coronavirus disease 2019 (COVID- 19) is being reported.
It is reported that there might be some mechanisms by which the dis-
ease can affect the central nervous system (CNS) (Li et al. 2020). De-
spite various neurological signs and symptoms, which have been re-
ported (Mao et al. 2020), there are only a few reported cases with
documented specific neurological processes to explain the CNS signs
(Liu et al. 2020). To our knowledge, no cases of post infectious en-
cephalitis (PIE) and its close follow up have been reported. Herein we
report a case with clinical (including respiratory and neurological),
laboratory, chest Computed Tomography and Brain Magnetic Re-
sonance Imaging (B-MRI) findings during evolution and convalescence
phase which can illuminate the natural history of similar cases.
2. Case report
A 39-year-old female presented to emergency department (ED) with
fever, myalgias, anorexia, drowsiness and dry cough. Fever and
myalgias had been present for nine days; she did not experience any
improvement with rest and anti-inflammatory drug (NSAIDS). She had
prolonged exposure to a covid-19 patient for prior 2 weeks. Past med-
ical history was otherwise insignificant.
After presentation to ED (day 10), she demonstrated a decline in
consciousness along with respiratory distress, ultimately needed en-
dotracheal intubation. Chest CT showed multiple peripheral patchy
ground-glass opacities with typical covid-19 distribution (day 10); these
opacities later formed bilateral peripheral consolidation (day 22)
(figure 1). She was transferred to intensive care unit (ICU) and treated
with broad-spectrum IV antibiotics (meropenem 1g tid, levofloxacin
750 mg daily, linezolide 600 bid), hydroxychloroqine 400 mg bid for
the first day, then 200 mg bid, atazanavir 400 mg daily and intravenous
immunoglobulin (IVIg) 25 g/day for 3 days. RT-polymerase chain re-
action (PCR) of a nasopharyngeal swab was negative for SARS-CoV 2
yet she was admitted with a diagnosis of Covid-19, based on clinical
history and chest CT scan findings.
The patient experienced an episode of self-limited generalized tonic-
clonic seizure (GTCS) on the following day (day 11) treated with in-
travenous (IV) levetiracetam 500 mg bid. She experienced another
episode of GTCS on the same day, managed with increment in
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levetiracetam dosage (500 mg tid). After improvement of respiratory
function, she was extubated (day 15). Despite improvement in in-
flammatory and metabolic tests, she had a fluctuating level of con-
sciousness. During investigation for decreased level of consciousness, B-
MRI revealed T2- fluid attenuated inversion recovery (FLAIR) high
signal intensities in bilateral thalami, medial temporal and pons
(figure 2). Corresponding areas in T1 images were hypo-signal and
without gadolinium enhancement or restriction on T1 post-contrast and
diffusion weighted imaging (DWI) sequences, respectively. Cere-
brospinal fluid (CSF) analysis showed normal protein (19 mg/dl) and
glucose (61 mg/dl) levels with no white or red blood cells. PCR tests for
detecting viruses including SARS-CoV 2 and herpes simplex virus in CSF
were negative. No oligoclonal bands (OCB) was detected. Autoimmune
serologic markers including SS-A/SS-B and Anti-phospholipid anti-
bodies were unremarkable. There was a borderline positive anti-nuclear
antibody (ANA=2.7, positive>1.2) result. Other laboratory tests and
their changes during disease course are listed in table 1. These results
led to the diagnosis of para- infectious encephalitis associated with
COVID-19 and treatment with IVIg continued to a total dosage of 3g/kg
of body weight (250g total) which resulted in considerable improve-
ment in consciousness, but discontinued because of headaches (day 28).
She complained of diplopia and was drowsy, even though the orienta-
tion seemed fully recovered (day 28). At this point, we continued the
treatment with high dose methylprednisolone (500mg/day) IV for 6
days, after which the diplopia resolved and she regained complete
consciousness. Subsequent B-MRIs (figure 2) showed marked resolution
Figure 1. Axial chest CT scans of the patient at days 10 (upper row), 22 (middle row) and 28 (bottom row) after onset of symptoms.
Figure 2. Three sets of axial (A-M except E) and coronal (E) brain MRIs obtained at days 11 (planes A1-M1), 22 (planes A2-M2) and 33 (planes A3-M3) after
symptoms onset, show the evolution of brain lesions over time. There are T2-FLAIR high signal lesions in bilateral pons (A1, B1, E1, F1 & G1), medial temporal lobes
(C1 & H1) and thalami (D1 & I1) and with low signal in T1 sequences (J1-M1). Corresponding images in second and third series show considerable resolution of
signal intense lesions. There was neither gadolinium enhancement nor diffusion restriction in post-contrast T1 and diffusion weighted imagings (not shown here).
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of medial temporal and thalami involvements as well as partial im-
provement in pontine lesions after reinstitution of IVIg (day 22) and
administration of methylprednisolone (day 33). Results of SARS-CoV 2
serology tests taken during admission became available after discharge
and were positive for both IgG and IgM.
3. Discussion
Brain involvement during COVID-19 pandemic has been reported in
various forms, but the prevalence and proportion of each type of in-
volvement is unknown (Mao et al. 2020, Liu et al. 2020). Stroke and
encephalitis are specific CNS disorders reported in COVID-19 but there
are many reports of neurological findings without obvious pathophy-
siologic explanations. The most common reported neurological mani-
festations have been headache, dizziness, encephalopathy and delirium.
Some of these patients have been undergone a neurological workup, yet
despite reports of CNS symptoms in up to 40% of these patients, there
are only few cases where distinct etiology has been discovered
(Liu et al. 2020). Among these there is only one established cases of
encephalitis with evidence of virus in CNS (Moriguchi et al. 2020) and
another case with acute necrotizing encephalitis (ANE) but without
evidence for direct viral invasion (Poyiadji et al. 2020). The distribution
of cerebral lesions in MRI for our patient was similar to both afore-
mentioned cases but with more extensive and symmetrical involvement
of thalami and medial temporal lobes. The involvement of pons has not
been present in previous reported cases. Contrary to the ANE case, in
our patient there was no evidence for hemorrhage or necrosis in serial
B-MRIs. A recent paper has described a number of B-MRI changes in
COVID-19 patients, but none of them have been the same as those in
our patient (Kandemirl et al. 2020). Although in ANE the authors
mentioned treatment with IVIg, but exact dosage, protocol and re-
sponse to treatment has not been described. Our patient before diag-
nosis of neurologic involvement had received IVIg (25 g/day for three
days) as a part of treatment for COVID-19 severe pulmonary involve-
ment; and after the CNS lesions were established, it was reinstituted and
due to very good clinical and radiological response, we decided to
continue IVIg therapy until complete recovery, unless there is a com-
plication. After administration of a total 250 g (3 g/kg) IVIg, it was
stopped due to occurrence of headaches that seemed related to drug
infusion. After discontinuation of IVIg, the headaches resolved com-
pletely and due to presence of diplopia and drowsiness treatment was
then continued with methylprednisolone (500 mg/day for six days),
which led to complete resolution of neurological symptoms. Upon
discharge from the hospital, the patient was completely asymptomatic.
We consider this type of brain involvement, a para- infectious auto-
immune encephalitis, as we believe was the case for ANE patient, and
recommend prompt immunotherapy upon diagnosis of similar cases.
The use of IVIg in severe COVID-19 patients may prevent or ameliorate
CNS involvement, as seemed to happen for our patient compared to
ANE case.
4. Conclusion
Neurological involvement in COVID-19 is increasingly reported and
the investigations regarding etiology, natural history and appropriate
treatment are essential. As for our patient, neurological symptoms not
correlated with respiratory and metabolic conditions should be an
alarm for the possibility of CNS involvement. Similar to many other
viral agents, SARS-CoV 2 seems capable of causing encephalitis. The
nature of etiology regarding encephalitis remains the matter of debate
as both direct invasion and para-infectious mechanisms seem possible.
We recommend prompt assessment of CSF for overt signs of viral in-
fection (marked cellular reaction, increased protein and positive PCR
test) and considering immunotherapy with IVIg in cases compatible
with para-infectious origin. The usefulness of prophylactic IVIg in se-
vere COVID-19 and the role of serology in CSF for diagnosing neu-
roinvasion, remain interesting discussions that we are unable to com-
ment about at this moment.
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